Page last updated: 2024-11-08
delta-n-hydroxyornithine
Description
delta-N-hydroxyornithine: constituent of ferrichromes; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N(5)-hydroxy-L-ornithine : A member of the class of hydroxylamines that is L-ornithine in which one of the N(5)-amino hydrogens is replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 169671 |
| CHEBI ID | 79095 |
| SCHEMBL ID | 11687971 |
| MeSH ID | M0046224 |
Synonyms (20)
| Synonym |
|---|
| dl-2-amino-5-hydroxylaminopentanoic acid |
| n5-hydroxy-l-ornithine |
| 35187-58-7 |
| (2s)-2-amino-5-(hydroxyamino)pentanoic acid |
| omega-n-hydroxyornithine |
| delta-n-hydroxyornithine |
| n(5)-hydroxy-l-ornithine |
| AKOS006338892 |
| CHEBI:79095 |
| n(5)-hydroxyornithine |
| C20850 |
| SCHEMBL11687971 |
| l-ornithine, n5-hydroxy- |
| n5-hydroxyornithine |
| l-n5-oh-ornithine |
| Q27147726 |
| (s)-2-amino-5-(hydroxyamino)pentanoic acid |
| DTXSID00956634 |
| n~5~-hydroxyornithine |
| (s)-2-amino-5-(hydroxyamino)pentanoicacid |
Drug Classes (4)
| Class | Description |
|---|
| L-ornithine derivative | An ornithine derivative resulting from reaction of L-ornithine at the amino group, the carboxy group or the side-chain amino group, or from the replacement of any hydrogen of L-ornithine by a heteroatom. |
| hydroxylamines | Hydroxylamine, H2N-OH, and its hydrocarbyl derivatives. |
| non-proteinogenic alpha-amino acid | Any alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
| amino acid zwitterion | The zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.30 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.09 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |